{"id":771045,"date":"2023-07-19T16:30:24","date_gmt":"2023-07-19T20:30:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\/"},"modified":"2023-07-19T16:30:24","modified_gmt":"2023-07-19T20:30:24","slug":"neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\/","title":{"rendered":"NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">MOUNTAIN VIEW, Calif., July  19, 2023  (GLOBE NEWSWIRE) &#8212; NeuroPace, Inc. (NASDAQ: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that it granted to Joel Becker, NeuroPace\u2019s recently-appointed Chief Executive Officer and director, an option to purchase 380,424 shares of NeuroPace\u2019s common stock at an exercise price of $4.39 under its 2023 Inducement Plan. The award was granted as an inducement material to Mr. Becker becoming a new employee of NeuroPace in accordance with The Nasdaq Stock Market Listing Rule 5635(c)(4).<\/p>\n<p>The award will vest over approximately four years, with 25% of the shares subject to the award vesting on July 10, 2024, and the remaining 75% of the shares subject to the award will vest in equal monthly installments over the following 36 months, subject to Mr. Becker\u2019s continuous service with NeuroPace through each such vesting date. The award is subject to the terms and conditions of NeuroPace\u2019s 2023 Inducement Plan and the terms and conditions of a stock option agreement covering the award.<\/p>\n<p>\n        <strong>About NeuroPace, Inc.<\/strong>\n      <\/p>\n<p>Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.<\/p>\n<p>\n        <strong>Investor Contact<\/strong>\n      <\/p>\n<p>Jeremy Feffer<br \/>Managing Director<br \/>LifeSci Advisors<br \/>jfeffer@lifesciadvisors.com<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3Njc3OCM1Njk4MzQzIzIyMDY1MzU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OGRlMjcwMDktYjM5ZC00YzVkLTlmNmMtNmFkNzNkYjA4NWM1LTEyMTgwODg=\/tiny\/NeuroPace-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MOUNTAIN VIEW, Calif., July 19, 2023 (GLOBE NEWSWIRE) &#8212; NeuroPace, Inc. (NASDAQ: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that it granted to Joel Becker, NeuroPace\u2019s recently-appointed Chief Executive Officer and director, an option to purchase 380,424 shares of NeuroPace\u2019s common stock at an exercise price of $4.39 under its 2023 Inducement Plan. The award was granted as an inducement material to Mr. Becker becoming a new employee of NeuroPace in accordance with The Nasdaq Stock Market Listing Rule 5635(c)(4). The award will vest over approximately four years, with 25% of the shares subject to the award vesting on July 10, 2024, and the remaining 75% of the shares &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-771045","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MOUNTAIN VIEW, Calif., July 19, 2023 (GLOBE NEWSWIRE) &#8212; NeuroPace, Inc. (NASDAQ: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that it granted to Joel Becker, NeuroPace\u2019s recently-appointed Chief Executive Officer and director, an option to purchase 380,424 shares of NeuroPace\u2019s common stock at an exercise price of $4.39 under its 2023 Inducement Plan. The award was granted as an inducement material to Mr. Becker becoming a new employee of NeuroPace in accordance with The Nasdaq Stock Market Listing Rule 5635(c)(4). The award will vest over approximately four years, with 25% of the shares subject to the award vesting on July 10, 2024, and the remaining 75% of the shares &hellip; Continue reading &quot;NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-19T20:30:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3Njc3OCM1Njk4MzQzIzIyMDY1MzU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market\",\"datePublished\":\"2023-07-19T20:30:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\\\/\"},\"wordCount\":286,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3Njc3OCM1Njk4MzQzIzIyMDY1MzU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\\\/\",\"name\":\"NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3Njc3OCM1Njk4MzQzIzIyMDY1MzU=\",\"datePublished\":\"2023-07-19T20:30:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3Njc3OCM1Njk4MzQzIzIyMDY1MzU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3Njc3OCM1Njk4MzQzIzIyMDY1MzU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\/","og_locale":"en_US","og_type":"article","og_title":"NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market - Market Newsdesk","og_description":"MOUNTAIN VIEW, Calif., July 19, 2023 (GLOBE NEWSWIRE) &#8212; NeuroPace, Inc. (NASDAQ: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that it granted to Joel Becker, NeuroPace\u2019s recently-appointed Chief Executive Officer and director, an option to purchase 380,424 shares of NeuroPace\u2019s common stock at an exercise price of $4.39 under its 2023 Inducement Plan. The award was granted as an inducement material to Mr. Becker becoming a new employee of NeuroPace in accordance with The Nasdaq Stock Market Listing Rule 5635(c)(4). The award will vest over approximately four years, with 25% of the shares subject to the award vesting on July 10, 2024, and the remaining 75% of the shares &hellip; Continue reading \"NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\/","og_site_name":"Market Newsdesk","article_published_time":"2023-07-19T20:30:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3Njc3OCM1Njk4MzQzIzIyMDY1MzU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market","datePublished":"2023-07-19T20:30:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\/"},"wordCount":286,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3Njc3OCM1Njk4MzQzIzIyMDY1MzU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\/","name":"NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3Njc3OCM1Njk4MzQzIzIyMDY1MzU=","datePublished":"2023-07-19T20:30:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3Njc3OCM1Njk4MzQzIzIyMDY1MzU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3Njc3OCM1Njk4MzQzIzIyMDY1MzU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuropace-announces-inducement-grants-under-listing-rule-5635c4-of-the-nasdaq-stock-market\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/771045","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=771045"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/771045\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=771045"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=771045"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=771045"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}